Get Started

NEUP

NASD Neuphoria Therapeutics Inc.
Nov 5, 2026 · 12:12 AM ET EOD Market Closed

$2.98 ↑ +0.00 (+0.00%) Trading Up from the previous close of $2.98, $0.09 below the day’s high of $3.07

YTD change
-23.20%
vs 20-day SMA
-9.78%
vs 200-day SMA
-28.22%

Price ranges

Previous day
$2.99 $3.05
open $3.01 close $2.99
-$0.02 (-0.66%)
Today
$2.98 $3.07
open $3.05 now $2.98
-$0.07 (-2.30%)
Past week
$2.99 $3.42
from $3.39 now $2.98
-$0.41 (-12.09%)
Past month
$2.99 $3.59
from $3.45 now $2.98
-$0.47 (-13.62%)
This year
$2.98 $5.53
from $3.88 now $2.98
-$0.90 (-23.20%)

Price & Performance

-2.31 (-43.67%) / 6M

$2.78$3.75$4.71$5.68May 4Aug 5Nov 4

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 86.1% away from all-time highs of $21.40
  • NEUP is down 23% since the beginning of the year
  • NEUP is down 29% over the past 12 months
  • NEUP is down 14% over the past 1 month
  • 0% of all NEUP investors are betting against NEUP

NEUP reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -29.4%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.9063
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $-6687820.0
Beta 1.53

Balance sheet & scale

IncomeN/A
Revenue$1.2M
Cash$19.9M
Debt$34.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $16.1M

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded in 1996 and is headquartered in Millis, MA.

Competitor comparison

TickerCompany PriceChange
REGN Regeneron Pharmaceuticals, Inc. $930.67 -4.39%
IQV IQVIA Holdings Inc $263.79 +0.46%
CRL Charles River Laboratories International, Inc. $326.29 -7.27%
ICLR ICON Plc $203.11 -0.32%
IT Gartner, Inc. $207.19 +1.45%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.